SAT goes digital - Covid-19 treatments paused - Unconditional income study

The F.D.A. said that it was limiting the emergency use authorizations of the Regeneron and Eli Lilly antibody treatments to say the infusions should not be used now, with Omicron dominant [at 99.5% of all new cases]. During a wave driven by Delta, those medications were effective at keeping infected people out of the hospital. As Omicron emerged, it became apparent that the treatments would not neutralize the virus.
...
Federal officials were rebuked by Republican governors saying they could still help some patients with the Delta variant. That has become an increasingly shaky position, given the difficulty most doctors have in figuring out which variant each patient has.
...
Since then, one monoclonal antibody treatment by GlaxoSmithKline and Vir Biotechnology has remained effective against Omicron, though doctors have said it is in short supply. Options for the early treatment of Covid continue to expand. On Friday, the F.D.A. approved the use of remdesivir for outpatients.